SEC Form 4 · accession 0001415889-18-000013
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura Brege
Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 6:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2018 | M | 15,000 | $8.06 | A | 15,000 | D | |
| Common Stock | Jan 2, 2018 | M | 10,000 | $8.49 | A | 25,000 | D | |
| Common StockF2 | Jan 2, 2018 | S | 25,000 | $30.0617 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F3 | $8.06 | Jan 2, 2018 | M | 15,000 | D | — | Apr 30, 2018 | Common Stock | 15,000 | 0 | D |
| Stock option (right to buy)F4 | $8.49 | Jan 2, 2018 | M | 10,000 | D | — | Jun 12, 2018 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in October 2017.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- F325% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of May 1, 2008.
- F425% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008.